Recently, a study comparing the impact of different biological DMARDs (namely tocilizumab, certolizumab pegol, and CTLA4-Ig) showed that different b-DMARDs have distinct effects on CD4pos cell phenotype in RA patients. The gene discussed is CTLA4; the disease is rheumatoid arthritis.